HARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES

Size: px
Start display at page:

Download "HARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES"

Transcription

1 HARVARD PILGRIM HEALTH CARE Generic Brand HICL GCN Exception/Other SOFOSBUVIR/VELPATASVIR EPCLUSA TBD CUSTOMER SERVICE REPRESENTATIVE (CSR) If the member lives in Rhode Island or if the prescribing physician s office is located in Rhode Island, then the CSR will enter an open-ended authorization for the medication, by HICL, regardless of the state in which the prescription is filled. The member s address should be verified through MedAccess. The physician s address may be verified through MedAccess or by asking the caller in which state the physician is located. (Due to state legislation, a RI physician is not required to submit medical or clinical information regarding a PA request). All other requests require a Medication Request Form (MRF) be submitted for review. PA COORDINATOR (PAC) If the member lives in Rhode Island or if the prescribing physician s office is located in Rhode Island, then an open-ended authorization should be entered for the medication, by HICL, regardless of the state in which the prescription is filled. The member s address should be verified through MedAccess. The physician s address may be verified through MedAccess or by verifying in which state the physician is located. (Due to state legislation, a RI physician is not required to submit medical or clinical information regarding a PA request). GUIDELINES FOR USE 1. Is the request for a patient with chronic hepatitis C with one of the following conditions? Gentoype 2 Genotype 3 Genotype 1, treatment-experienced w/ compensated cirrhosis and ribavirin ineligible Gentoype 4, treatment-experienced (Please note: Harvoni is also indicated; however, the level of evidence is higher w/ Epclusa) If yes, continue to #3. If no, continue to #2. 2. Has the prescriber indicated that treatment with Harvoni would be clinically inappropriate, or that the patient was or will be unable to tolerate treatment with Harvoni? If yes, continue to #3. If no, do not approve. Please use status code #238 and the provided denial text. medication is only covered for patients in whom treatment with Harvoni (ledipasvir/sofosbuvir) would be clinically inappropriate or who were, or will be, unable to tolerate treatment with Harvoni. Your physician did not indicate that treatment with Harvoni would be clinically inappropriate or that you were, or will be, unable to tolerate treatment with Harvoni and therefore your Coverage of Harvoni requires prior authorization. You should discuss with your physician if prior authorization for treatment with Harvoni should be requested. Revised: 7/06/2016 Page 1 of 6

2 GUIDELINES FOR USE (CONTINUED) 3. Is the patient at least 18 years old? HARVARD PILGRIM HEALTH CARE If yes, continue to #4. medication is only covered for members 18 years of age and older. Your physician indicated that you are under the age of 18 and therefore your 4. Is the requested medication being prescribed by a gastroenterologist, infectious disease specialist, physician specializing in the treatment of hepatitis (e.g. hepatologist)? If yes, continue to #5. medication is only covered when prescribed by a gastroenterologist, infectious disease specialist, or a physician specializing in the treatment of hepatitis (e.g. hepatologist). Your physician did not indicate that he or she specializes in one of these areas and therefore your 5. Does the patient have end stage renal disease, or require dialysis? medication is not covered for patients who have end stage renal disease (ESRD) or require dialysis. Your physician indicated that you have ESRD or require dialysis and therefore your If no, continue to #6. 6. Has the patient been counseled regarding the potential for antacids, H2 blockers and proton pump inhibitors, including over-the-counter (OTC) medications, to decrease the efficacy of Epclusa? If yes, continue to #7. medication is covered for patients who have been counseled regarding the potential for acidreducing medications (e.g. antacids, H2 blockers and proton pump inhibitors) to decrease the effectiveness of Epclusa. Your physician has not indicated that you have been counseled on the drug interactions between Epclusa and acid-reducing medications and therefore your Revised: 7/06/2016 Page 2 of 6

3 GUIDELINES FOR USE (CONTINUED) HARVARD PILGRIM HEALTH CARE 7. Is the patient currently taking any of the following medications: amiodarone, atorvastatin, carbamazepine, phenytoin, phenobarbital, oxcarbazepine, rifampin, rifabutin, rifapentine, rosuvastatin, or St. John s Wort? DENIAL TEXT: Per your health plan s Sofosbuvir/Velpatasvir (Epclusa) guideline, FDAapproved product information recommends the following medications not be taken with Epclusa: amiodarone, atorvastatin, carbamazepine, phenytoin, phenobarbital, oxcarbazepine, rifampin, rifabutin, rifapentine, rosuvastatin, or St. John s Wort. Your physician indicated that you are currently taking one of these medications and therefore your If no, continue to #8. 8. Does the patient have a history of a liver transplant? medication is not covered for patients who have had a liver transplant because there are other medications that should be used, such as Harvoni. Your physician indicated that you had a liver transplant and therefore your Plesae discuss alternative options with your provider. If no, continue to #9. 9. Has the patient s liver disease been staged using either an invasive or non-invasive testing method (e.g. liver biopsy confirming METAVIR score, transient elastography (Fibroscan) score, FibroTest/FibroSURE score, APRI score, or radiological imaging) within the past 3 years? If yes, continue to #10. medication is only covered when the degree of liver disease has been staged using an invasive or non-invasive test within the past 3 years and documentation has been submitted. Your physician did not indicate that your liver disease has been staged within the past 3 years and/or did not provide documentation and therefore your requested was not approved. Revised: 7/06/2016 Page 3 of 6

4 HARVARD PILGRIM HEALTH CARE GUIDELINES FOR USE (CONTINUED) 10. Does the patient have evidence of stage 2 or greater hepatic fibrosis indicated by one of the following: Liver biopsy confirming a METAVIR score of F2, F3 or F4 Ishak score > 3 Transient elastography (Fibroscan) score > 7.5 kpa FibroTest (FibroSURE) score > 0.48 Radiological imaging demonstrating cirrhosis (e.g. evidence of portal hypertension or ascites) If yes, continue to #11. If no, do not approve. Please use status code #238 and the denial text below. medication is only covered for patients with moderate to advanced scarring of the liver (fibrosis) or compensated cirrhosis as indicated by one of the following test results: a liver biopsy METAVIR score of F2 or greater, an Ishak score of 3 or greater, a Fibroscan score of 7.5 kpa or greater, a FibroSURE score of 0.48 or greater, or radiological imaging demonstrating cirrhosis. Your physician did not indicate that you have moderate to advanced scarring of the liver or compensated cirrhosis and therefore your 11. Has the provider attested that the patient is not currently participating in illicit substance abuse or alcohol abuse, or that the patient is receiving substance or alcohol abuse counseling services as an adjunct to HCV treatment? If yes, continue to #12. medication is only covered for patients who are not actively participating in illicit substance abuse or alcohol abuse, or who are receiving substance or alcohol abuse counseling services. Your physician indicated that you are either currently abusing illicit substances or alcohol, or are not receiving substance or alcohol abuse counseling services and therefore your request was not approved. 12. Is the patient co-infected with HIV? If yes, continue to #13. If no, continue to # Is the patient s antiretroviral regimen being managed by a physician specializing in the treatment of HIV? If yes, continue to #14. medication is covered for patients with HIV co-infection whose medications used to treat his or her HIV (called antiretroviral medications) are being managed by a physician specializing in the treatment of HIV. Your physician did not indicate that your antiretroviral medication regimen is being managed by a physician specializing in the treatment of HIV and therefore your request was not approved. Revised: 7/06/2016 Page 4 of 6

5 GUIDELINES FOR USE (CONTINUED) HARVARD PILGRIM HEALTH CARE 14. During treatment with Epclusa, will the patient be taking an antiretroviral regimen containing one of the fllowing: efavirenz (Sustiva; Atripla), etravirine (Intelence), or tipranavir (Aptivus) concomitantly with ritonavir (Norvir; Kaletra)? medication is not covered for patients with HIV co-infection who will be taking certain medications used to treat his or her HIV (called antiretroviral medications) during treatment with Epclusa. These antiretroviral medications include efavirenz (Sustiva; Atripla),etravirine (Intelence), and tipranavir (Aptivus) when taken with ritonavir (Norvir, Kaletra), and any other products containing one of these active ingredients. Your physician indicated that during treatment with Epclusa you will be taking at least one of these antiretroviral medications and therefore your If no, continue to # During treatment with Epclusa, will the patient be taking an antiretroviral regimen containing tenofovir disoproxyl fumarate (Viread; Complera; Stribild)? If yes, continue to #16. If no, continue to # Is the patient s creatinine clearance (CrCl) < 60mL/min? medication is not covered for patients with HIV co-infection and reduced kidney function who will also be taking a tenofovir disoproxyl fumarate-containing medication during treatment with Epclusa. Your physician indicated that you have reduced kidney function and during treatment with Epclusa you will be taking a medication containing tenofovir disoproxyl fumarate and therefore your A different formulation of tenfovor is available that may be a treatment option when taken during treatment with Epclusa. Please discuss this with your provider. If no, continue to # Does the patient have one of the following conditions? Decompensated cirrhosis Gentoype 2 or 3 and treatment-experienced with sofosbuvir Gentoype 3 with compensated cirrhosis and treatment-experienced with peg-ifn/ribavirin If yes, continue to #18. If no, continue to #19. Revised: 7/06/2016 Page 5 of 6

6 HARVARD PILGRIM HEALTH CARE 18. Did the provider indicate that Epclusa will be administered in combination with ribavirin? If yes, continue to #19 medication is only covered for certain conditions (e.g., decompensated cirrhosis, genotype 2 or 3 and previously treated with sofosbuvir, or genotype 3 with cirrhosis and previously treated with pegylated-interferon and ribavirin) when used in combination with ribavirin. Your physician did not indicate that you will be taking Epclusa in combination with ribavirin and therefore your 19. Approve by HICL for 12 weeks with a fill count of 3. (A quantity limit of one tablet per day is hard-coded). Please use status code #056 and the following approval language: APPROVAL TEXT (Eplcusa without ribavirin): Your request for Epclusa has been approved with a quantity limit of one tablet per day for a 12-week period. APPROVAL TEXT (Epclusa with ribavirin): Your request for Epclusa has been approved with a quantity limit of one tablet per day for a 12-week period. Please note, it is very important that ribavirin be taken together with Epclusa during your 12 weeks of treatment to improve the likelihood that your condition will be cured. Do not start therapy until you have both ribavirin and Epclusa. If you have any questions, speak with your provider. RATIONALE Ensure appropriate utilization of Epclusa (sofosbuvir/velpatasvir) based on FDA approved indication. FDA APPROVED INDICATIONS For the treatment of adult patients with chronic hepatitis C genotype 1, 2, 3, 4, 5, or 6 infection. FDA APPROVED DOSAGE One 400mg/100mg tablet taken once daily with or without food. Treatment regimen and duration in patients with genotypes 1, 2, 3, 4, 5 or 6: Patient Population Patients without cirrhosis and patients with compensated cirrhosis (Child-Pugh A) Patients with decompensated cirrhosis (Child-Pugh B and C) Recommended Treatment Regimen Epclusa for 12 weeks Epclusa + ribavirin for 12 weeks REFERENCES Guidance from the American Association for the Study of Liver Diseases (AASLD) and the Infectious Disease Society of America (IDSA) Recommendations for Testing, Managing, and Treating Hepatitis C. Available online at Updated February 24, Accessed July 6, Epclusa [Prescribing Information]. Foster City, CA: Gilead Sciences; June Created: 7/7/16 Effective: 7/8/16 P&T Approval: 9/12/16 Revised: 7/06/2016 Page 6 of 6

SOFOSBUVIR/VELPATASVIR Generic Brand HICL GCN Exception/Other SOFOSBUVIR/ VELPATASVIR

SOFOSBUVIR/VELPATASVIR Generic Brand HICL GCN Exception/Other SOFOSBUVIR/ VELPATASVIR Generic Brand HICL GCN Exception/Other SOFOSBUVIR/ VELPATASVIR EPCLUSA 43561 GUIDELINES FOR USE 1. Is the patient at least 18 years old? If yes, continue to #2. 2. Does the patient have a diagnosis of

More information

HARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES

HARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES HARVARD PILGRIM HEALTH CARE Generic Brand HICL GCN Exception/Other DACLATASVIR DAKLINZA 41377 ELBASVIR/GRAZOPREVIR ZEPATIER 43030 GLECAPREVIR/PIBRENTASVIR MAVYRET 44453 OMBITASVIR/PARITAPREVIR/ RITONAVIR

More information

REQUEST FOR PRIOR AUTHORIZATION Hepatitis C Treatments

REQUEST FOR PRIOR AUTHORIZATION Hepatitis C Treatments Fax completed form to: 866-940-7328 Prior Authorization Phone Number: 800-310-6826 IA Medicaid Member ID # Patient name Date of Birth Patient address Patient phone Provider NPI Prescriber name Phone Prescriber

More information

Hepatits C Criteria Direct Acting Antiviral Medications

Hepatits C Criteria Direct Acting Antiviral Medications Hepatits C Criteria Direct Acting Antiviral Medications Harvoni-Formulary PA required 1. Is the patient being treated for a funded condition by the Oregon Health Plan? 2. Does the member have a diagnosis

More information

INFECTIOUS DISEASE AGENTS: HEPATITIS C - DIRECT - ACTING ANTIVIRAL

INFECTIOUS DISEASE AGENTS: HEPATITIS C - DIRECT - ACTING ANTIVIRAL Ohio Department of Medicaid Prior Authorization Form Unified PDL HEPATITIS C TREATMENT Member ID# Patient Name: DOB: Patient Address: Provider DEA: Provider NPI: Provider Name: Phone: Provider Address:

More information

AmeriHealth Caritas Iowa Request for Prior Authorization Hepatitis C Treatments

AmeriHealth Caritas Iowa Request for Prior Authorization Hepatitis C Treatments Form applies to IA Health Link and hawk-i plans. Please print accuracy is important. Fax completed form to 1-855-825-2714. Provider Help Desk: 1-855-328-1612. AmeriHealth Caritas Iowa member ID #: Patient

More information

State of Maine Department of Health & Human Services MaineCare/MEDEL Prior Authorization Form HEPATITIS C TREATMENT

State of Maine Department of Health & Human Services MaineCare/MEDEL Prior Authorization Form HEPATITIS C TREATMENT State of Maine Department of Health & Human Services MaineCare/MEDEL Prior Authorization Form HEPATITIS C TREATMENT HCV Phone: 1-888-445-0497 www.mainecarepdl.org Fax: 1-888-879-6938 Member ID #: Patient

More information

State of Maine Department of Health & Human Services MaineCare/MEDEL Prior Authorization Form HEPATITIS C TREATMENT

State of Maine Department of Health & Human Services MaineCare/MEDEL Prior Authorization Form HEPATITIS C TREATMENT State of Maine Department of Health & Human Services MaineCare/MEDEL Prior Authorization Form HEPATITIS C TREATMENT HCV Phone: 1-888-445-0497 www.mainecarepdl.org Fax: 1-888-879-6938 Member ID #: Patient

More information

Protocol for daclatasvir (Daklinza ) Approved October 2015 (updated February 2018)

Protocol for daclatasvir (Daklinza ) Approved October 2015 (updated February 2018) PREFERRED AGENTS: (See drug specific NOTES for exceptions.) Protocol for daclatasvir (Daklinza ) Approved October 2015 (updated February 2018) https://providers.amerigroup.com For genotype 1, Mavyret and

More information

Outpatient Pharmacy Effective Date: August 15, 2014

Outpatient Pharmacy Effective Date: August 15, 2014 Therapeutic Class Code: W5Y, W5V, W0B, W0D, W0A, W0E Therapeutic Class Description: Hepatitis C Virus nucleotide analog NS5B RNA Dependent Polymerase Inhibitor, Hepatitis C Virus NS3/4A Serine Protease

More information

Harvoni. Harvoni (ledipasvir & sofosbuvir) Description

Harvoni. Harvoni (ledipasvir & sofosbuvir) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Harvoni Page: 1 of 7 Last Review Date: June 19, 2015 Harvoni Description Harvoni (ledipasvir &

More information

Harvoni. Harvoni (ledipasvir & sofosbuvir) Description

Harvoni. Harvoni (ledipasvir & sofosbuvir) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.03.32 Subject: Harvoni Page: 1 of 7 Last Review Date: December 3, 2015 Harvoni Description Harvoni (ledipasvir

More information

Hepatitis C Genotype 1 (GT 1) Patients in the United States (US)

Hepatitis C Genotype 1 (GT 1) Patients in the United States (US) Hepatitis C Genotype 1 (GT 1) Patients in the United States (US) INDICATION is indicated with or without ribavirin for the treatment of patients with chronic hepatitis C virus (HCV) genotype 1, 4, 5, or

More information

MEDICAL POLICY EFFECTIVE DATE: 9/1/2016 REVISED DATE: 1/1/2017

MEDICAL POLICY EFFECTIVE DATE: 9/1/2016 REVISED DATE: 1/1/2017 Page 1 of 19 DESCRIPTION: Hepatitis C Drug Coverage Criteria For all Regimens (see individual drugs for drug specific requirements). Based upon our assessment of the peer-reviewed literature, the drugs

More information

Harvoni. Harvoni (ledipasvir & sofosbuvir) Description

Harvoni. Harvoni (ledipasvir & sofosbuvir) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.32 Subject: Harvoni Page: 1 of 9 Last Review Date: March 18, 2016 Harvoni Description Harvoni (ledipasvir

More information

Harvoni. Harvoni (ledipasvir & sofosbuvir) Description

Harvoni. Harvoni (ledipasvir & sofosbuvir) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.32 Subject: Harvoni Page: 1 of 9 Last Review Date: December 2, 2016 Harvoni Description Harvoni (ledipasvir

More information

PHARMACY PRIOR AUTHORIZATION Hepatitis C Clinical Guideline

PHARMACY PRIOR AUTHORIZATION Hepatitis C Clinical Guideline PHARMACY PRIOR AUTHORIZATION Hepatitis C Clinical Guideline Preferred Regimen Based on Diagnosis: Mavyret (glecaprevir/pibrentasvir ) Non-Preferred: Daklinza (daclatasvir) Epclusa (sofosbuvir/velpatasvir)

More information

Pharmacy Medical Necessity Guidelines: Medications for the Treatment of Hepatitis C

Pharmacy Medical Necessity Guidelines: Medications for the Treatment of Hepatitis C Pharmacy Medical Necessity Guidelines: Medications for the Treatment of Hepatitis C Effective: March 13, 2018 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical

More information

Update on Real-World Experience With HARVONI

Update on Real-World Experience With HARVONI Update on Real-World Experience With A RESOURCE FOR PAYERS This information is intended for payers only. The HCV-TARGET and TRIO studies were supported by Gilead Sciences, Inc. Real-world experience data

More information

Hepatitis C Direct-Acting Antivirals

Hepatitis C Direct-Acting Antivirals Hepatitis C Direct-Acting Antivirals Goals: Approve use of cost-effective treatments supported by the medical evidence. Provide consistent patient evaluations across all hepatitis C treatments. Ensure

More information

Length of Authorization: 8-12 weeks. Requires PA: All direct-acting antivirals for treatment of Hepatitis C. Approval Criteria

Length of Authorization: 8-12 weeks. Requires PA: All direct-acting antivirals for treatment of Hepatitis C. Approval Criteria Hepatitis C Direct-Acting Antivirals Goals: Approve use of cost-effective treatments supported by the medical evidence. Provide consistent patient evaluations across all hepatitis C treatments. Ensure

More information

Prior Authorization Guideline

Prior Authorization Guideline Prior Authorization Guideline Guideline Name Sovaldi (sofosbuvir) Formulary UnitedHealthcare Community & State Formulary Note Approval Date 2/19/2014 Revision Date 7/8/2014 1. Indications Drug Name: Sovaldi

More information

PHARMACY PRIOR AUTHORIZATION Hepatitis C Clinical Guideline

PHARMACY PRIOR AUTHORIZATION Hepatitis C Clinical Guideline Preferred Regimen Based on Diagnosis: Mavyret (glecaprevir/pibrentasvir) PHARMACY PRI AUTHIZATION Hepatitis C Clinical Guideline Non-Preferred: Daklinza (daclatasvir) Epclusa (sofosbuvir/velpatasvir) Harvoni

More information

Hepatitis C Medications Prior Authorization Criteria

Hepatitis C Medications Prior Authorization Criteria Hepatitis C Medications Authorization Criteria Epclusa (/velpatasvir), Harvoni (ledipasvir/), Sovaldi (), Daklinza (daclatasvir), Zepatier (elbasvir/grazoprevir), Olysio (simeprevir), Viekira Pak (ombitasvir/paritaprevir/ritonavir;

More information

Clinical Policy: Daclatasvir (Daklinza) Reference Number: ERX.SPA.131 Effective Date:

Clinical Policy: Daclatasvir (Daklinza) Reference Number: ERX.SPA.131 Effective Date: Clinical Policy: (Daklinza) Reference Number: ERX.SPA.131 Effective Date: 10.01.16 Last Review Date: 08.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal

More information

2017 United Healthcare Services, Inc.

2017 United Healthcare Services, Inc. UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 2055-10 Program Prior Authorization/Medical Necessity Medication Olysio (simeprevir) P&T Approval Date 4/2015, 11/2015, 8/2016,

More information

Length of Authorization: 8-16 weeks. Requires PA: All direct-acting antivirals for treatment of Hepatitis C. Approval Criteria

Length of Authorization: 8-16 weeks. Requires PA: All direct-acting antivirals for treatment of Hepatitis C. Approval Criteria Hepatitis C Direct-Acting Antivirals Goals: Approve use of cost-effective treatments supported by the evidence. Provide consistent patient evaluations across all hepatitis C treatments. Ensure appropriate

More information

Harvoni (sofosbuvir/ledipasvir

Harvoni (sofosbuvir/ledipasvir Market DC Override(s) Prior Authorization Quantity Limit (sofosbuvir/ledipasvir) Approval Duration Based on Genotype, Treatment status, Baseline HCV RNA status, Cirrhosis status, Transplant status, or

More information

Hepatitis C Medications Hawaii PRIOR AUTHORIZATION REQUEST FORM

Hepatitis C Medications Hawaii PRIOR AUTHORIZATION REQUEST FORM Please complete this entire form and fax it to: 866-940-7328. If you have questions, please call 800-310-6826. This form contains multiple pages. Please complete all pages to avoid a delay in our decision.

More information

Prior Approval Criteria Hepatitis C Virus Medications DRAFT

Prior Approval Criteria Hepatitis C Virus Medications DRAFT Therapeutic Class Code: W5Y, W5V, W0B, W0D, W0A, W0E Therapeutic Class Description: Hepatitis C Virus nucleotide analog NS5B RNA Dependent Polymerase Inhibitor, Hepatitis C Virus NS3/4A Serine Protease

More information

Prior Authorization Guideline

Prior Authorization Guideline Prior Authorization Guideline Guideline Name Olysio (simeprevir) Formulary UnitedHealthcare Community & State Formulary Note Approval Date 2/19/2014 Revision Date 7/9/2014 1. Indications Drug Name: Olysio

More information

Clinical Policy: Sofosbuvir (Sovaldi) Reference Number: OH.PHAR.PPA.12 Effective Date: Last Review Date: 12.18

Clinical Policy: Sofosbuvir (Sovaldi) Reference Number: OH.PHAR.PPA.12 Effective Date: Last Review Date: 12.18 Clinical Policy: (Sovaldi) Reference Number: OH.PHAR.PPA.12 Effective Date: 01.19 Last Review Date: 12.18 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important

More information

Epclusa (Sofosbuvir/Velpatasvir) for HIV/HCV

Epclusa (Sofosbuvir/Velpatasvir) for HIV/HCV Mountain West AIDS Education and Training Center Epclusa (Sofosbuvir/Velpatasvir) for HIV/HCV John Scott, MD, MSc Associate Professor University of Washington Jul 28, 2016 This presentation is intended

More information

Length of Authorization: 8-16 weeks. Requires PA: All direct-acting antivirals for treatment of Hepatitis C. Approval Criteria

Length of Authorization: 8-16 weeks. Requires PA: All direct-acting antivirals for treatment of Hepatitis C. Approval Criteria Hepatitis C Direct-Acting Antivirals Goals: Approve use of cost-effective treatments supported by the evidence. Provide consistent patient evaluations across all hepatitis C treatments. Ensure appropriate

More information

Clinical Policy: Ledipasvir/Sofosbuvir (Harvoni) Reference Number: OH.PHAR.PPA.10 Effective Date: Last Review Date: 12.18

Clinical Policy: Ledipasvir/Sofosbuvir (Harvoni) Reference Number: OH.PHAR.PPA.10 Effective Date: Last Review Date: 12.18 Clinical Policy: (Harvoni) Reference Number: OH.PHAR.PPA.10 Effective Date: 01.19 Last Review Date: 12.18 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important

More information

Length of Authorization: 8-16 weeks. Requires PA: All direct-acting antivirals for treatment of Hepatitis C. Approval Criteria

Length of Authorization: 8-16 weeks. Requires PA: All direct-acting antivirals for treatment of Hepatitis C. Approval Criteria Hepatitis C Direct-Acting Antivirals Goals: Approve use of cost-effective treatments supported by the medical evidence. Provide consistent patient evaluations across all hepatitis C treatments. Ensure

More information

Molina Healthcare of Texas Hepatitis C Drugs (Medicaid)

Molina Healthcare of Texas Hepatitis C Drugs (Medicaid) Texas Standard Prior Authorization Form Addendum Molina Healthcare of Texas Hepatitis C Drugs (Medicaid) This fax machine is located in a secure location as required by HIPAA Regulations. Complete / Review

More information

Description of Antivirals for Hepatitis C. LCDR Dwayne David, PharmD, BCPS, NCPS Cherokee Nation Infectious Diseases

Description of Antivirals for Hepatitis C. LCDR Dwayne David, PharmD, BCPS, NCPS Cherokee Nation Infectious Diseases Description of Antivirals for Hepatitis C LCDR Dwayne David, PharmD, BCPS, NCPS Cherokee Nation Infectious Diseases Dwayne-David@cherokee.org Objectives Compare the different classes of direct-acting antiviral

More information

Part I. Prior Authorization Criteria and Policy

Part I. Prior Authorization Criteria and Policy Texas Vendor Drug Program Antiviral Agents for Hepatitis C Virus Initial Authorization Request (Medicaid) Part I. Prior Authorization Criteria and Policy March 2018-E I. Eligibility 1. Patient is enrolled

More information

Gilead to Present Wide-Ranging New Data on Treatment and Diagnosis of Liver Diseases at The Liver Meeting 2018

Gilead to Present Wide-Ranging New Data on Treatment and Diagnosis of Liver Diseases at The Liver Meeting 2018 Gilead to Present Wide-Ranging New Data on Treatment and Diagnosis of Liver Diseases at The Liver Meeting 2018 October 11, 2018 3:24 PM ET -- More Than 50 Abstracts Across NASH, PSC, HBV and HCV Reflect

More information

Clinical Policy: Sofosbuvir/Velpatasvir (Epclusa) Reference Number: OH.PHAR.PPA.05 Effective Date: Last Review Date: 12.18

Clinical Policy: Sofosbuvir/Velpatasvir (Epclusa) Reference Number: OH.PHAR.PPA.05 Effective Date: Last Review Date: 12.18 Clinical Policy: (Epclusa) Reference Number: OH.PHAR.PPA.05 Effective Date: 01.19 Last Review Date: 12.18 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important

More information

Update on Real-World Experience With HARVONI

Update on Real-World Experience With HARVONI Update on Real-World Experience With A RESOURCE FOR PAYERS MAY 217 This information is intended for payers only. The HCV-TARGET study was supported by Gilead Sciences, Inc. Real-world experience data were

More information

Clinical Criteria for Hepatitis C (HCV) Therapy

Clinical Criteria for Hepatitis C (HCV) Therapy Clinical Criteria for Hepatitis C (HCV) Therapy Pre-Treatment Evaluation o Must have chronic hepatitis C and HCV genotype and sub-genotype documented; o Patients who have prior exposure to DAA therapy

More information

SASKATCHEWAN FORMULARY BULLETIN Update to the 62nd Edition of the Saskatchewan Formulary

SASKATCHEWAN FORMULARY BULLETIN Update to the 62nd Edition of the Saskatchewan Formulary April 1, 2017 Bulletin #165 ISSN 1923-0761 SASKATCHEWAN FORMULARY BULLETIN Update to the 62nd Edition of the Saskatchewan Formulary Related Information for Prescribers: Only prescribers who have completed

More information

Hepatitis C Infection: Updated Information for Front Line Workers in Primary Care Settings MAMTA K. JAIN, MD, MPH 2/14/18

Hepatitis C Infection: Updated Information for Front Line Workers in Primary Care Settings MAMTA K. JAIN, MD, MPH 2/14/18 Hepatitis C Infection: Updated Information for Front Line Workers in Primary Care Settings MAMTA K. JAIN, MD, MPH 2/14/18 Overview Hepatitis C Virus Prevalence Effects of Hepatitis C Prevention Diagnosis

More information

Harvoni (Ledipasvir/Sofosbuvir) Information Packet

Harvoni (Ledipasvir/Sofosbuvir) Information Packet Harvoni (Ledipasvir/Sofosbuvir) Information Packet Family Medicine Provider: If you are considering hepatitis C treatment, please read this treatment agreement carefully and be sure to ask any questions

More information

Clinical Policy: Glecaprevir/Pibrentasvir (Mavyret) Reference Number: CP.PHAR.348 Effective Date: 09/17

Clinical Policy: Glecaprevir/Pibrentasvir (Mavyret) Reference Number: CP.PHAR.348 Effective Date: 09/17 Clinical Policy: (Mavyret) Reference Number: CP.PHAR.348 Effective Date: 09/17 Last Review Date: 09/17 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important

More information

Harvoni (ledipasvir + sofosbuvir)

Harvoni (ledipasvir + sofosbuvir) FACTSHEET Harvoni (ledipasvir + sofosbuvir) Summary Harvoni is a medication used to treat hepatitis C. It is approved in Canada for people with genotype 1 hepatitis C virus. Harvoni is a combination of

More information

Clinical Criteria for Hepatitis C (HCV) Therapy

Clinical Criteria for Hepatitis C (HCV) Therapy Clinical Criteria for Hepatitis C (HCV) Therapy Pre-Treatment Evaluation o Must have chronic hepatitis C and HCV genotype and sub-genotype documented; o Patients who have prior exposure to DAA therapy

More information

Address: City: State: ZIP code: Inferferon Product Requested (Include Strength):

Address: City: State: ZIP code: Inferferon Product Requested (Include Strength): Please complete this entire form and fax it to: 866-940-7328. If you have questions, please call 800-310-6826. This form contains multiple pages. Please complete all pages to avoid a delay in our decision.

More information

California Department of Health Care Services Utilization and Treatment Policy for Simeprevir and Sofosbuvir in the Management of Hepatitis C

California Department of Health Care Services Utilization and Treatment Policy for Simeprevir and Sofosbuvir in the Management of Hepatitis C Introduction California Department of Health Care Services Utilization and Treatment Policy for Simeprevir and Sofosbuvir in the Management of Hepatitis C This policy was developed by the California Department

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Viekira XR, Viekira Pak) Reference Number: ERX.SPA.129 Effective Date: 10.01.16 Last Review Date: 08.17 Line of Business: Commercial [Prescription Drug Plan] Revision Log See Important

More information

Clinical Policy: Sofosbuvir/Velpatasvir (Epclusa) Reference Number: OH.PHAR.PPA.05 Effective Date: 07/17 Last Review Date: 09/17

Clinical Policy: Sofosbuvir/Velpatasvir (Epclusa) Reference Number: OH.PHAR.PPA.05 Effective Date: 07/17 Last Review Date: 09/17 Clinical Policy: (Epclusa) Reference Number: OH.PHAR.PPA.05 Effective Date: 07/17 Last Review Date: 09/17 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important

More information

Daklinza Sovaldi. Daklinza (daclatasvir) and Sovaldi (sofosbuvir) Description

Daklinza Sovaldi. Daklinza (daclatasvir) and Sovaldi (sofosbuvir) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.36 Subject: Daklinza Page: 1 of 8 Last Review Date: March 18, 2016 Daklinza Description Daklinza (daclatasvir)

More information

Clinical Policy: Elbasvir/Grazoprevir (Zepatier) Reference Number: OH.PHAR.PPA.08 Effective Date: Last Review Date: 12.18

Clinical Policy: Elbasvir/Grazoprevir (Zepatier) Reference Number: OH.PHAR.PPA.08 Effective Date: Last Review Date: 12.18 Clinical Policy: (Zepatier) Reference Number: OH.PHAR.PPA.08 Effective Date: 01.19 Last Review Date: 12.18 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important

More information

Harvoni (ledipasvir + sofosbuvir)

Harvoni (ledipasvir + sofosbuvir) Harvoni (ledipasvir + sofosbuvir) Summary Harvoni is a medication used to treat hepatitis C. It is approved in Canada for people with all genotypes of the hepatitis C virus. Harvoni is a combination of

More information

Pharmacy Medical Necessity Guidelines: Hepatitis C Virus

Pharmacy Medical Necessity Guidelines: Hepatitis C Virus Pharmacy Medical Necessity Guidelines: Hepatitis C Virus Effective: January 1, 2018 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review Pharmacy (RX)

More information

Sovaldi (sofosbuvir)

Sovaldi (sofosbuvir) Market DC Sovaldi (sofosbuvir) Override(s) Prior Authorization Quantity Limit Approval Duration Based on Genotype, Treatment status, Cirrhosis status, or Ribavirin Eligibility status **IN, SC, WA Medicaid

More information

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Medical Policy An independent licensee of the Blue Cross Blue Shield Association Hepatitis C First Generation Agents Page 1 of 18 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: See also: Hepatitis C First Generation Agents - Through Preferred

More information

Vosevi (sofosbuvir/velpatasvir/voxilaprevir)

Vosevi (sofosbuvir/velpatasvir/voxilaprevir) Vosevi (sofosbuvir/velpatasvir/voxilaprevir) Policy Number: 5.01.646 Last Review: 10/2017 Origination: 10/2017 Next Review: 11/2018 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide

More information

SUMMACARE COMMERCIAL MEDICATION REQUEST GUIDELINES

SUMMACARE COMMERCIAL MEDICATION REQUEST GUIDELINES Generic Brand HICL GCN Exception/Other TELAPREVIR INCIVEK 37629 This drug requires a written request for prior authorization. All requests for hepatitis C medications require review by a pharmacist prior

More information

Hepatitis C (Direct Acting Antiviral Medications for Treatment of Hepatitis C) QUEST Integration Formulary

Hepatitis C (Direct Acting Antiviral Medications for Treatment of Hepatitis C) QUEST Integration Formulary Hepatitis C (Direct Acting Antiviral Medications for Treatment of Hepatitis C) QUEST Integration Formulary Policy Number: Original Effective Date: MM.04.036 06/01/2015 Lines of Business: Current Effective

More information

Clinical Criteria for Hepatitis C (HCV) Therapy

Clinical Criteria for Hepatitis C (HCV) Therapy Clinical Criteria for Hepatitis C (HCV) Therapy Pre-Treatment Evaluation o Must have chronic hepatitis C and HCV genotype and sub-genotype documented; o Patients who have prior exposure to DAA therapy

More information

Clinical Criteria for Hepatitis C (HCV) Therapy

Clinical Criteria for Hepatitis C (HCV) Therapy Diagnosis Clinical Criteria for Hepatitis C (HCV) Therapy Must have chronic hepatitis C (HCV infection > 6 months), genotype and sub-genotype specified to determine the length of therapy; Liver biopsy

More information

Daclatasvir (Daklinza ) Drug Interactions with HIV Medications

Daclatasvir (Daklinza ) Drug Interactions with HIV Medications Daclatasvir/Sofosbuvir (Daklinza /Sovaldi TM ) Drug Interactions A Quick Guide for Clinicians April 2017 John J Faragon, PharmD, BCPS, AAHIVP Mechanism of Action and Route of Metabolism for Daclatasvir

More information

Clinical Policy: Sofosbuvir/Velpatasvir/Voxilaprevir (Vosevi) Reference Number: GA.PMN.25 Product: Medicaid Effective Date: 9/17

Clinical Policy: Sofosbuvir/Velpatasvir/Voxilaprevir (Vosevi) Reference Number: GA.PMN.25 Product: Medicaid Effective Date: 9/17 Clinical Policy: Sofosbuvir/Velpatasvir/Voxilaprevir (Vosevi) Reference Number: GA.PMN.25 Product: Medicaid Effective Date: 9/17 Last Review Date: 9/17 Revision Log See Important Reminder at the end of

More information

Daklinza Sovaldi. Daklinza (daclatasvir) and Sovaldi (sofosbuvir) Description

Daklinza Sovaldi. Daklinza (daclatasvir) and Sovaldi (sofosbuvir) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Daklinza Sovaldi Page: 1 of 7 Last Review Date: June 24, 2016 Daklinza Sovaldi Description Daklinza

More information

Clinical Policy: Ombitasvir/Paritaprevir/Ritonavir (Technivie) Reference Number: CP.PHAR.276 Effective Date: Last Review Date: 08.

Clinical Policy: Ombitasvir/Paritaprevir/Ritonavir (Technivie) Reference Number: CP.PHAR.276 Effective Date: Last Review Date: 08. Clinical Policy: (Technivie) Reference Number: CP.PHAR.276 Effective Date: 09.16 Last Review Date: 08.18 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Sovaldi) Reference Number: ERX.SPA.127 Effective Date: 10.01.16 Last Review Date: 08.17 Line of Business: Commercial [Prescription Drug Plan] Revision Log See Important Reminder at the

More information

JOHNS HOPKINS HEALTHCARE

JOHNS HOPKINS HEALTHCARE JOHNS HOPKINS HEALTHCARE Subject: Clinical Criteria for Hepatitis C (HCV) Therapy Department: Pharmacy Lines of Business: PPMCO Policy Number: MEDS92 Effective Date: 04/15/2015 Revision Date: 08/15/2015

More information

Prior Authorization. Drug Name (select from list of drugs shown) Viekira Pak (ombitasv-paritaprev-ritonav-dasabuv) Quantity Frequency Strength

Prior Authorization. Drug Name (select from list of drugs shown) Viekira Pak (ombitasv-paritaprev-ritonav-dasabuv) Quantity Frequency Strength 06/01/2016 Prior Authorization Aetna Better Health Texas Viekara Pak w or w/o Ribavirin First Fill (Med) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review

More information

Epclusa (Sofosbuvir/Velpatasvir) Treatment Agreement

Epclusa (Sofosbuvir/Velpatasvir) Treatment Agreement Epclusa (Sofosbuvir/Velpatasvir) Treatment Agreement Liver Disease & Hepatitis Program Providers: Brian McMahon, MD; Youssef Barbour, MD; Lisa Townshend-Bulson, FNP-C; Annette Hewitt, FNP-C; Prabhu Gounder,

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Epclusa) Reference Number: CP.HNMC.38 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Medicaid Medi-Cal Revision Log See Important Reminder at the end of this policy

More information

Hepatitis C (Direct Acting Antiviral Medications for Treatment of Hepatitis C) Fibrosis Score Requirement QUEST Integration

Hepatitis C (Direct Acting Antiviral Medications for Treatment of Hepatitis C) Fibrosis Score Requirement QUEST Integration Hepatitis C (Direct Acting Antiviral Medications for Treatment of Hepatitis C) Fibrosis Score Requirement QUEST Integration Policy Number: Original Effective Date: MM.04.036 06/01/2015 Lines of Business:

More information

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Medical Policy An independent licensee of the Blue Cross Blue Shield Association Hepatitis C Second Generation Antivirals Page 1 of 32 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: See also: Hepatitis C Second Generation Antivirals Through

More information

Clinical Policy: Daclatasvir (Daklinza) Reference Number: ERX.SPMN.180

Clinical Policy: Daclatasvir (Daklinza) Reference Number: ERX.SPMN.180 Clinical Policy: (Daklinza) Reference Number: ERX.SPMN.180 Effective Date: 10/16 Last Review Date: 09/16 Coding Implications Revision Log See Important Reminder at the end of this policy for important

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Epclusa) Reference Number: CP.CPA.286 Effective Date: 11.01.16 Last Review Date: 08.18 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important

More information

Clinical Policy: Dasabuvir/ombitasvir/paritaprevir/ritonavir (Viekira XR, Viekira Pak) Reference Number: ERX.SPMN.178

Clinical Policy: Dasabuvir/ombitasvir/paritaprevir/ritonavir (Viekira XR, Viekira Pak) Reference Number: ERX.SPMN.178 Clinical Policy: (Viekira XR, Viekira Pak) Reference Number: ERX.SPMN.178 Effective Date: 10/16 Last Review Date: 09/16 Coding Implications Revision Log See Important Reminder at the end of this policy

More information

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Medical Policy An independent licensee of the Blue Cross Blue Shield Association Hepatitis C First Generation Agents Page 1 of 16 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: See also: Hepatitis C First Generation Agents - Through Preferred

More information

Criteria for Indiana Medicaid Hepatitis C Agents

Criteria for Indiana Medicaid Hepatitis C Agents Prepared for State of Indiana by OptumRx EXECUTIVE SUMMARY Purpose: Promote prudent prescribing of Setting & Population: All members Type of Criteria: Increased Risk of ADE Non-Preferred Agent Appropriate

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Daklinza) Reference Number: HIM.PA.SP27 Effective Date: Last Review Date: 01/17 Line of Business: Health Insurance Marketplace Coding Implications Revision Log See Important Reminder

More information

New Exception Status Benefits

New Exception Status Benefits APRIL 2018 Nova Scotia Formulary Updates New Exception Status Benefits Lenvima Updates for Hepatitis C Medications Daklinza Epclusa Harvoni Sovaldi Zepatier New Diabetic Product New Ostomy Products Nova

More information

Clinical Policy: Daclatasvir (Daklinza) Reference Number: CP.PHAR.274 Effective Date: 09/16 Last Review Date: 09/17 Line of Business: Medicaid

Clinical Policy: Daclatasvir (Daklinza) Reference Number: CP.PHAR.274 Effective Date: 09/16 Last Review Date: 09/17 Line of Business: Medicaid Clinical Policy: (Daklinza) Reference Number: CP.PHAR.274 Effective Date: 09/16 Last Review Date: 09/17 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Vosevi) Reference Number: CP.HNMC.41 Effective Date: 07.26.17 Last Review Date: 11.17 Line of Business: Medicaid Medi-Cal Revision Log See Important Reminder at the end of this policy

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: Dasabuvir, Ombitasvir, Paritaprevir, Ritonavir (Viekira XR, Viekira Pak) Reference Number: OH.PHAR.PPA.09 Effective Date: 07/17 Last Review Date: 09/17 Line of Business: Medicaid See Important

More information

Highlights in the Treatment of Hepatitis C Virus From the 2016 AASLD Liver Meeting

Highlights in the Treatment of Hepatitis C Virus From the 2016 AASLD Liver Meeting December 16 Volume 12, Issue 12, Supplement 6 A SPECIAL MEETING REVIEW EDITION Highlights in the Treatment of Hepatitis C Virus From the 16 AASLD Liver Meeting A Review of Selected Presentations From the

More information

Clinical Policy: Elbasvir/grazoprevir (Zepatier) Reference Number: ERX.SPMN.181

Clinical Policy: Elbasvir/grazoprevir (Zepatier) Reference Number: ERX.SPMN.181 Clinical Policy: (Zepatier) Reference Number: ERX.SPMN.181 Effective Date: 10/16 Last Review Date: 09/16 Coding Implications Revision Log See Important Reminder at the end of this policy for important

More information

Primary Care Approach to Diagnosis and Management of Chronic Hepatitis C Brian Viviano, D.O.

Primary Care Approach to Diagnosis and Management of Chronic Hepatitis C Brian Viviano, D.O. Primary Care Approach to Diagnosis and Management of Chronic Hepatitis C Brian Viviano, D.O. Objectives Epidemiology of chronic hepatitis C CDC guidelines on screening or hepatitis C Diagnosing hepatitis

More information

Clinical Policy: Glecaprevir/Pibrentasvir (Mavyret) Reference Number: GA.PMN.24 Product: Medicaid Effective Date: 9/17

Clinical Policy: Glecaprevir/Pibrentasvir (Mavyret) Reference Number: GA.PMN.24 Product: Medicaid Effective Date: 9/17 Clinical Policy: Glecaprevir/Pibrentasvir (Mavyret) Reference Number: GA.PMN.24 Product: Medicaid Effective Date: 9/17 Last Review Date: 9/17 Revision Log See Important Reminder at the end of this policy

More information

Daklinza Sovaldi. Daklinza (daclatasvir) and Sovaldi (sofosbuvir) Description

Daklinza Sovaldi. Daklinza (daclatasvir) and Sovaldi (sofosbuvir) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Daklinza Sovaldi Page: 1 of 4 Last Review Date: September 18, 2015 Daklinza Sovaldi Description

More information

Topic: Sovaldi, sofosbuvir Date of Origin: March 14, Committee Approval Date: August 15, 2014 Next Review Date: March 2015

Topic: Sovaldi, sofosbuvir Date of Origin: March 14, Committee Approval Date: August 15, 2014 Next Review Date: March 2015 Medication Policy Manual Policy No: dru332 Topic: Sovaldi, sofosbuvir Date of Origin: March 14, 2014 Committee Approval Date: August 15, 2014 Next Review Date: March 2015 Effective Date: October 1, 2014

More information

RATIONALE FOR INCLUSION IN PA PROGRAM

RATIONALE FOR INCLUSION IN PA PROGRAM RATIONALE FOR INCLUSION IN PA PROGRAM Background Hepatitis C is a viral disease that causes inflammation of the liver that can lead to diminished liver function or liver failure. Most people infected with

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: () Reference Number: OH.PHAR.PPA.08 Effective Date: 07/17 Last Review Date: 09/17 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important

More information

2017 UnitedHealthcare Services, Inc.

2017 UnitedHealthcare Services, Inc. UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 2052-10 Program Prior Authorization/Medical Necessity Medication Harvoni (ledipasvir/sofosbuvir) P&T Approval Date 4/2015, 8/2015,

More information

2017 UnitedHealthcare Services, Inc.

2017 UnitedHealthcare Services, Inc. UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 1146-7 Program Prior Authorization/Notification Medication Harvoni (ledipasvir/sofosbuvir) P&T Approval Date 10/2014, 2/2015,

More information

DATE: 6/03 LAST REVIEW DATE:

DATE: 6/03 LAST REVIEW DATE: SUBJECT: Chronic Hepatitis C (Pegasys, Peg-Intron, ribavirin, Olysio, Sovaldi, Harvoni, ledipasvir/sofosbuvir, Viekira, Viekira XR, Daklinza, Technivie, Zepatier, Epclusa, sofosbuvir/velpatasvir, Vosevi,

More information

Clinical Policy: Simeprevir (Olysio) Reference Number: OH.PHAR.PPA.11 Effective Date: 07/17 Last Review Date: 09/17 Line of Business: Medicaid

Clinical Policy: Simeprevir (Olysio) Reference Number: OH.PHAR.PPA.11 Effective Date: 07/17 Last Review Date: 09/17 Line of Business: Medicaid Clinical Policy: (Olysio) Reference Number: OH.PHAR.PPA.11 Effective Date: 07/17 Last Review Date: 09/17 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important

More information

Sovaldi + Olysio + ribavirin Harvoni + ribavirin. Sovaldi + ribavirin Viekira Pak

Sovaldi + Olysio + ribavirin Harvoni + ribavirin. Sovaldi + ribavirin Viekira Pak Hepatitis Prior Authorization Request CVS Caremark administers the specialty pharmacy benefit plan for the patient identified. This patient s benefit plan requires prior authorization for certain medications

More information

Hepatitis C Agents

Hepatitis C Agents Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.41 Subject: Hepatitis C Agents Page: 1 of 20 Last Review Date: March 16, 2018 Hepatitis C Agents Description

More information